Acadia Pharmaceuticals | ACAD - Selling And Administration Expenses

Stock Price
20.61
Daily Change
-0.66 -3.10%
Monthly
-10.20%
Yearly
17.77%
Q1 Forecast
19.99

Acadia Pharmaceuticals reported $146.73M in Selling and Administration Expenses for its fiscal quarter ending in December of 2025.





Selling And Administration Expenses Change Date
Acadia Pharmaceuticals USD 146.73M 21.82M Dec/2025
ALKERMES USD 187.2M 15.43M Dec/2025
Alnylam Pharmaceuticals USD 285.06M 22.47M Dec/2025
Biogen USD 545.2M 38.6M Sep/2025
BioMarin Pharmaceutical USD 322.21M 98.79M Dec/2025
Bristol-Myers Squibb USD 2.18B 392M Dec/2025
Cara Therapeutics USD 4.64M 2.19M Mar/2025
Corcept Therapeutics USD 114.74M 7.77M Dec/2025
Cytokinetics USD 91.72M 67.02M Dec/2025
Eisai JPY 111.72B 7.86B Dec/2025
Eli Lilly USD 3.13B 391.3M Dec/2025
Incyte USD 390.41M 61.33M Dec/2025
J&J USD 6.75B 831M Dec/2025
Moderna USD 308M 40M Dec/2025
Neurocrine Biosciences USD 301.8M 10.2M Dec/2025
Pfizer USD 4.08B 894M Dec/2025
Prothena USD 13.24M 2.67M Sep/2025
PTC Therapeutics USD 87.2M 3.15M Dec/2025
Sarepta Therapeutics USD 105.38M 28.27M Dec/2025
Ultragenyx Pharmaceutical USD 89M 2.38M Dec/2025
Vanda Pharmaceuticals USD 39.28M 1.71M Dec/2024
Vertex Pharmaceuticals USD 487M 41.9M Dec/2025